Effect of sodium tanshinone II A sulfonate on cardiac myocyte hypertrophy and its underlying mechanism
- Jun Feng冯 俊Affiliated withDepartment of Emergency Internal Medicine, Tongji Hospital, Huazhong University of Science and Technology Email author
- , Zhi Zheng郑 智Affiliated withDepartment of Emergency Internal Medicine, Tongji Hospital, Huazhong University of Science and Technology
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To investigate the effects of sodium tanshinone II A sulfonate (STS) on the hypertrophy induced by angiotensin II (Ang II) in primary cultured neonatal rat cardiac myocytes.
The effect of STS on cytotoxicity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-3,5-phenytetrazoliumromide (MTT) assay. As indexes for cardiocyte hypertrophy, cell size was determined by phase contrast microscopy and protein synthesis rate was measured by 3H-leucine incorporation. The proto-oncogene c-fos mRNA expression of cardiocytes was assessed using reverse transcription polymerase chain reaction (RT-PCR).
STS could inhibit cardiocyte hypertrophy, increase the protein synthesis rate and enhance proto-oncogene c-fos mRNA expression in cardiocytes induced by Ang II (P<0.01), with an effect similar to that of Valsartan, the Ang II receptor antagonist.
STS can prevent the hypertrophy of cardiac myocytes induced by Ang II, which may be related to its inhibition of the expression of proto-oncogene c-fos mRNA.
Key Wordssodium tanshinone II A sulfonate angiotensin II cardiac myocyte hypertrophy c-fos
- Effect of sodium tanshinone II A sulfonate on cardiac myocyte hypertrophy and its underlying mechanism
Chinese Journal of Integrative Medicine
Volume 14, Issue 3 , pp 197-201
- Cover Date
- Print ISSN
- Online ISSN
- Chinese Association of Traditional and Western Medicine
- Additional Links
- sodium tanshinone II A sulfonate
- angiotensin II
- cardiac myocyte hypertrophy
- Industry Sectors